Singapore markets close in 2 hours 18 minutes

NVO Jul 2024 167.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.01000.0000 (0.00%)
As of 12:25PM EDT. Market open.
Full screen
Loading interactive chart…
  • Zacks

    NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss

    A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.

  • Benzinga

    Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds

    A new observational study has identified a potential link between Novo Nordisk A/S’s (NYSE:NVO) GLP-1 drugs, Ozempic and Wegovy (semaglutide), and a serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss. NAION refers to a loss of blood flow to the optic nerve (the cable that connects the eye to the brain). This condition typically causes sudden vision loss in one eye without any pain. Also Read: Joe Biden Suggests Novo Nordisk, Eli

  • Yahoo Finance Video

    Weight-loss drugs linked to rare vision loss: Harvard study

    Novo Nordisk (NVO) and Eli Lilly (LLY) shares dip in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss. Yahoo Finance health reporter Anjalee Khemlani explains the study's findings. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.